STUDY QUESTION: What is the prevalence of malignant testicular germ cell tumors (TGCT) and its precursors, (pre-) germ cell neoplasia in situ (GCNIS), in late teenagers and adults who have androgen insensitivity syndrome (AIS) and the impact of an individual's genetic susceptibility to development of TGCT?
Introduction
Until the 21st century, bilateral gonadectomy was typically performed in childhood following a diagnosis of 46,XY complete or partial androgen insensitivity syndrome (CAIS, PAIS) in individuals raised in the female sex, given that the historically reported increased risk of malignant testicular germ cell tumors (TGCT) (Cools et al., 2006) . Reassuring data regarding TGCT risk in AIS during childhood have since led to a testis sparing approach (Hughes et al., 2012) , as many affected individuals prefer to retain their gonads to take advantage of the benefits of endogenous hormone secretion. In individuals with CAIS, postponing gonadectomy until late adolescence allows for breast development, bone mass accrual and a pubertal growth spurt through peripheral aromatization of androgens to oestrogens. Around 15% of adult women with CAIS subsequently refuse gonadectomy (Deans et al., 2012) . These women pose a challenge to caregivers given the absence of reliable tumor biomarkers and the lack of data regarding TGCT development in CAIS during adulthood . Individuals with PAIS are now increasingly assigned to male sex for rearing (Kolesinska et al., 2014) and their testes are retained. However, apart from early orchidopexy of non-scrotal gonads, regular self-examination, ultrasound and possibly testicular biopsy, no specific recommendations for long-term monitoring have been made (Hughes et al., 2012; van der Zwan et al., 2015) .
The risk for development of TGCT specifically in adults with AIS has never been investigated. Available estimates are derived from combining historical case series of patients who have undergone gonadectomy after puberty. In a French study of 16 postpubertal girls (age range 11-18, mean 14 years) with molecularly confirmed CAIS, the precursor lesion carcinoma in situ (CIS), now officially termed germ cell neoplasia in situ (GCNIS) by the World Health Organization (Ulbright et al., 2016) , was diagnosed in one girl (6.3%) (Cheikhelard et al., 2008) . No malignancies were reported in 21 postpubertal woman (age range 14-40, mean 21 years) with molecularly confirmed CAIS in a Spanish study, however, testicular histology could be revised in only 13 of them (Audi et al., 2010) . In a British study, 25 adult women (age range 17-39, mean 23 years) with molecularly confirmed CAIS underwent magnetic resonance imaging of their gonads, followed by gonadectomy in 13. No invasive tumors were detected in any of them, however three had premalignant changes (Nakhal et al., 2013) . These series predict a combined GCNIS prevalence of 4/42 (9.5%) postpubertal girls and adult women with CAIS between the ages of 11 and 40 years.
The histological changes in the testis in individuals with CAIS (age range 3 months to 18 years), of which 9 were (post)pubertal, were recently described (Kaprova-Pleskacova et al., 2014) . The seminiferous tubules are generally atrophic (fibrosed and Sertoli cell-only) with very few germ cells (GCs), depending on age and residual androgen receptor (AR) activity. Twelve gonads of six women with CAIS older than 13 years had no GCs. Two postpubertal women had pre-GCNIS, and one had GCNIS, as defined in the most recent WHO classification (Ulbright et al., 2016) . These data and personal observations suggest that the prevalence of invasive TGCT is substantially lower than the prevalence of GCNIS, implying that progression of GCNIS to a TGCT is a (very) rare event (Kaprova-Pleskacova et al., 2014) .
Invasive TGCT in AIS can be seminoma, non-seminoma or a mixture of both (Cools et al., 2005; Stoop et al., 2008) . No reliable TGCT biomarkers are currently available for the surveillance of testes at risk for progression to an invasive tumor . In contrast to nonseminomas, GCNIS and seminoma, being the most frequent neoplasia in AIS, do not typically secrete proteins (e.g. β-hCG, α-fetoprotein) (Schmoll et al., 2004) . Moreover, GCNIS cannot be visualized by ultrasound or MRI (Nakhal et al., 2013) . TGCT, including GCNIS, express specific microRNAs, that have potential roles as biomarkers when secreted into body fluids such as serum and semen (Dieckmann et al., 2012) . A recently developed diagnostic test based on the targeted detection of TGCT-specific microRNAs shows promising results for the diagnosis of early TGCT (Gillis et al., 2013) but not GCNIS (Van Agthoven and Looijenga, 2016) .
Genome-wide association studies (GWAS) have identified a number of single nucleotide polymorphisms (SNPs) related to TGCT development in the male population. A risk stratification model has been proposed based on the combined presence of one or more of these risk alleles in an individual's genotype (Kratz et al., 2011; Chung et al., 2013) . Independently, a polymorphic response element for the tumor suppressor p53 within the promotor region of the KITLG gene (encoding KIT ligand) has been identified as an important genetic variant possibly underlying TGCT susceptibility (Zeron-Medina et al., 2013) . Whether genetic susceptibility is a factor involved in TGCT development in AIS or other differences of sex development has never been examined.
For the above reasons, there has been a strong demand for studies assessing TGCT risk in postpubertal individuals with AIS specifically and to help inform individualized management guidelines. We performed detailed immunohistochemical studies in a relatively large series of biopsy and gonadectomy samples from postpubertal individuals with AIS aged 14 years or older. To avoid bias caused by inclusion of patients with other conditions, only cases with a genetically confirmed diagnosis of AIS were included. Concomitantly, we performed genotyping of fourteen known TGCT susceptibility alleles and correlated these data to the histopathological findings. These SNPs are all significantly related to TGCC (OR 1.19 or higher in at least two GWAS studies), and map within or close to biologically relevant candidate genes for disease-, gonadal-or GC development (Kanetsky et al., 2011; Kratz et al., 2011; Chung et al., 2013; Zeron-Medina et al., 2013; Litchfield et al., 2017) .
Materials and methods

Ethics
The study was approved by the ethics review committees of the Ghent University Hospital (MEC 2008/098) 
Tissue
Through international collaboration, we collected 97 gonadal tissue samples from 52 patients with a genetically confirmed AR mutation (42 CAIS, 10 PAIS) ( Table I ). Samples were fixed in formalin and sent as paraffin blocks or 3-5 μm slides on coated glasses. All surgical procedures had been performed with informed consent of the patients and/or their legal guardians.
Immunohistochemistry
Slides were pre-treated with 3% H 2 O 2 for 5 min, biotin blocked (Vector SP-2001) 
Morphological/immunohistochemical criteria for GCNIS and preceding lesions
The criteria were according to Ulbright et al. (2016) . Delayed maturation of gonocytes is indicated by expression of octamer-binding protein 3/4 (OCT3/4) in centrally located gonocytes beyond the age of 6 months. Pre-GCNIS is indicated by gonocytes, relocated from the center of the tubules to the (pre-)spermatogonial niche at the basement membrane, which fail to switch off OCT3/4 expression and may co-express OCT3/4 and TSPY in a heterogeneous pattern, accompanied by focal expression of stem cell factor, alternatively called KIT Ligand (KITLG). The nuclei of pre-GCNIS cells lack the characteristic features of the nuclei of GCNIS cells. GCNIS is indicated by atypical gonocytes with enlarged, hyperchromatic and angulated nuclei located at the basement membrane, with consistent expression of OCT3/4 usually with co-expression of TSPY, and accompanied by diffuse KITLG expression in Sertoli cells and, in an autocrine fashion, in GCNIS cells.
Confirmation of AR mutation
Sanger sequencing of the full coding sequence of the AR gene was performed according to standardized local procedures using genomic DNA extracted from peripheral leukocytes. All mutations are reported based on the coding DNA reference sequence according to Human Genome Variation Society (HGVS) nomenclature (Table I) .
SNP analysis
Genomic DNA was extracted from whole blood (if available) or tissue samples according to standardized procedures. Genotyping of all selected loci was based on published methods (Chung et al., 2013; Zeron-Medina et al., 2013) (Table II) using TaqMan ® SNP Genotyping Assays (Life Technologies/Thermo Fisher Scientific, Bleiswijk, The Netherlands). Fluorescent signal for allelic discrimination was obtained after PCR amplification using an end-point reading on the 7500 Fast Real-Time System (Life Technologies). Automatic allele calling was performed with allelic discrimination plot software (SDS 2.3, Life Technologies). The SNPs selected for this study are all identified as significantly related to TGCC susceptibility (OR 1.19 or higher), and all map within or close to biologically relevant candidate genes for disease-, gonadal-or GC development (see Table I and Supplementary Table 1 for additional information). Furthermore the SNPs nearby all genes specified in this study, with the exception of PPM1E, have been identified in at least two independent GWAS studies (Kanetsky et al., 2011; Kratz et al., 2011; Chung et al., 2013; Zeron-Medina et al., 2013; Litchfield et al., 2017) .
GSS determination
The genetic susceptibility score (GSS) for developing a TGCT was calculated for each patient as follows: for each risk allele, the genotype frequency of the risk allele was multiplied by the corresponding per allele odds ratio (OR). The genotype frequency of the risk allele can be either 0, 1 or 2, depending on the number of actual risk alleles in the patients' genotype. The sum of these individual products equals the GSS of that patient (Kratz et al., 2011; Chung, et al., 2013) . Because of the absence of an OR for the SNP rs4590952, this SNP was not included in the GSS analyses, but was investigated separately.
Statistics
IBM SPSS Statistics 22 was used for statistical analyses. Data that were not normally distributed are expressed as median (25th-75th percentile), unless otherwise stated. The Mann-Whitney U-test was used for comparison of non-parametric continuous variables.
Results
Testicular tissue samples (n = 97) were obtained from 42 women with CAIS and 10 individuals with PAIS (6 men and 4 women). Four individuals with PAIS from two unrelated families (one from Germany, one from Morocco) had the same, frequently occurring (Gottlieb et al., 2012) mutation (Table I, Table I . Due to the retrospective nature of our study some patient data could not be retrieved. All procedures were performed for prophylactic reasons (gonadectomy, 44 patients; biopsy, 8 patients), sometimes after visualization of a testicular nodule on ultrasound or MRI. All but two individuals (Table I , patients 1 and 7) are of Caucasian origin, from various countries. A schematic overview of the study design as well as results is given in Fig. 1 . GC, independent of their state, were present in 51/80 CAIS (64%) and 15/17 (88%) PAIS samples. Diffusely distributed GC throughout the testicular tissue investigated were more often present in PAIS than in CAIS (Fig. 2) . As reported previously, hamartomas, Sertoli cell only nodules, branching tubules, thickening of the basal membrane, intertubular fibrosis, tubular atrophy and Leydig cell hyperplasia were common (Cools et al., 2005; Hannema et al., 2006 , Kaprova-Pleskacova et al., 2014 . Lumen formation and limited spermatogenesis were seen in some PAIS, but not in CAIS, samples.
Invasive TGCT or GCNIS were not encountered in this series. In contrast, pre-GCNIS was found in tissue samples from 7/52 (13%) individuals, who had a median age of 15 (range 14-22) years at the To avoid inconsistent results for calculation of the GSS, two SNPs were excluded from the series of originally selected targets, i.e. rs210138 (BAK1, per allele OR 1.53) and rs7040024 (DMRT1, per allele OR 1.7) due to poor data quality in some patients. This is likely explained by the fact that DNA had to be extracted from paraffin blocks in these patients, resulting in poor quality and the impact of the amplicon size of these SNPs. In addition, rs459052 was not included in the GSS score (see text) because of the lack of an OR.
time of surgery. Two of them (patient 20 and 42) had, in the months before, experienced some discomfort in the groin region where their testes were located; the decision to perform the procedure had been taken after an ultrasound exam, yielding a heterogeneous appearance of the testes. AR mutations were in the ligand-binding domain in 5/7 cases, in line with the known frequency distribution of AR mutations causing AIS (Gottlieb et al., 2012) . One of ten individuals with PAIS (10%) had unilateral pre-GCNIS in an inguinal gonad removed at 15 years. Pre-GCNIS was found in nine samples (9/80, 11.3%) from six (6/42, 14.2%) women with CAIS whose testes were removed at ages 14-22 years. Two of these women (patients 28 and 29) were first cousins. Bilateral samples were available in five out of six cases, in three of these, the lesions were bilateral. Fig. 3 displays representative images.
DNA was available from 36/52 (69%) individuals, including six out of seven cases with pre-GCNIS. Allelic discrimination failed for two SNPs (rs210138, BAK1, per allele OR 1.53 and rs7040024, DMRT1, per allele OR 1.7) in most cases where DNA had to be extracted from the paraffin blocks, yielding inconsistent results for calculation of the GSS. This is likely related to poor quality of the isolated DNA, in addition to the amplicon size of the specific genotyping assays for these SNPs. Therefore, results for these SNPs were excluded from further analysis from the original set of SNPs. Based on the 14 remaining SNPs included in this study (see Table I ), all cases were investigated. The socalled GSS was calculated based on 13 of these 14 SNPS given that for rs4590952, no OR is currently known. The GSS represents a patient specific score related to the total sum of the individual SNP-risk allele frequency multiplied by the corresponding allele OR. The GSS differed significantly in cases with and without pre-GCNIS (median [25th-75th percentile] respectively 26.2 [24.7-36.9] versus 23.2 [21.0-25.3]; P = 0.01) (Fig. 4A) . Of specific note is the observation that within this series for two SNPs (KITLG, rs995030 and ATF7IP, RS2900333), all six tested pre-GCNIS cases were homozygous for the risk alleles (G and C respectively). Both genes have been related to cancer development previously (Stoop et al., 2008; Turnbull et al., 2010) . For these two SNPs, allele frequency distribution differed significantly between cases with and without pre-GCNIS (rs995030: P = 0.05, rs2900333: P = 0.04).
Because of the absence of an OR for the SNP rs4590952, this SNP is investigated separately. Allele frequency for the risk allele G at the p53 binding site on the KITLG promotor (rs4590952) did not differ between individuals with or without pre-GCNIS: four of six pre-GCNIS cases (66%) were homozygous as compared to 24/38 (63%) cases without pre-GCNIS (Fig. 4B) .
Discussion
TGCT risk in AIS is lower than in many other disorders of sex development (DSDs) (Cools et al., 2006) . A major drawback in previous studies is that estimates of TGCT risk in CAIS are based on gonads Figure 1 Schematic overview of the design of the study, both related to patients included as well as to SNPs investigated. Note that two of the original series of targets were excluded due to technical reasons (see text), resulting in a final list of 14 SNPs (see Table I ). One of these SNPs lacks an odds ratio (OR), and was therefore not included in the final genetic susceptibility score (GSS). CAIS/PAIS: complete/partial androgen insensitivity syndrome: GCNIS: germ cell neoplasia in situ; TGCT: testicular germ cell tumor. removed prophylactically early in life (Cools et al., 2005 (Cools et al., , 2006 . Clinical practice has changed, with gonadectomy mostly being postponed until late adolescence (Hughes et al., 2012) . However, teenagers and women with CAIS increasingly object to gonadectomy, even when counseled about the limitations of available TGCT screening modalities (Deans et al., 2012) . Furthermore, children with PAIS are increasingly raised male, and for them, avoiding gonadectomy is crucial (Kolesinska et al., 2014) . The lack of data regarding long-term TGCT risk in both CAIS and PAIS raises management challenges for patients and clinicians.
Three factors contribute to the relatively low TGCT risk in AIS (van der Zwan et al., 2015) . First, testes develop normally in AIS, in contrast to 46,XY gonadal dysgenesis, where TGCT risk is much higher. Second, many GCs undergo apoptosis early and therefore have no capacity for neoplastic transformation (Cools et al., 2005) , and third, the lack of paracrine androgen signaling may play a crucial role. Androgens promote GC proliferation, mediated via Sertoli cells (Cools et al., 2011; O'Shaughnessy, 2014) . Immature Sertoli cells of typical testes lack AR and therefore this effect only appears around puberty (Rey, 2014) . AIS is characterized by deficient androgen signaling. However, Wolffian duct development in CAIS has been attributed to residual paracrine androgen activity (Hannema et al., 2004) . We hypothesize that in AIS, similarly, residual paracrine androgen signaling may promote neoplastic GC proliferation from puberty onwards, resulting in increased TGCT risk in adulthood. We addressed this question by investigating the occurrence of the earliest described lesions predisposing to TGCT, as well as more advanced stages, in a large series of AIS gonads obtained at ages 14 years and older. To understand why only some individuals with AIS develop TGCTs, we correlated our results to an estimation of each individual's genetic susceptibility to develop TGCT, based on a selection of assumed relevant (see Supplementary Table 1) high-risk SNPs identified in studies of testicular GC cancer in men (Kratz et al., 2011; Chung et al., 2013; Zeron-Medina et al., 2013) .
No invasive TGCT or extensive GCNIS were encountered in our series containing almost 100 samples from 52 postpubertal individuals with CAIS and PAIS. Pre-GCNIS was present in 6/42 women with CAIS (14.2%) and 11/80 samples (11.3%). One pre-GCNIS lesion was found in 1/10 individuals with PAIS (1/17 samples, 5.9%). These percentages are comparable to combined data from other series (Cheikhelard et al., 2008; Audi et al., 2010; Nakhal et al., 2013) . Surprisingly, in the current series, pre-GCNIS was not found more often in individuals who have PAIS as compared to CAIS, in contrast to earlier findings from our group (Cools et al., 2005 (Cools et al., , 2006 . Moreover, in cases who had pre-GCNIS, the clinical phenotype mostly corresponded with that of other reported cases. TGCT incidence in typical men differs largely among populations, with Caucasian men having the highest incidence (Juniarto et al., 2013; Ghazarian et al., 2015) . Given that only two individuals from our series are nonCaucasian, our study is not informative regarding this issue.
Based on our genotyping assay, the GSS for developing TGCT was significantly higher in individuals with pre-GCNIS as compared to those without such lesions, suggesting that genetic susceptibility is one of the factors involved in TGCT in AIS. However, there was considerable overlap between the groups. Therefore we conclude that although indicative, this approach as a whole is currently insufficiently discriminatory as a guidance tool for management, e.g. regarding prophylactic gonadectomy. Likewise, homozygosity for the reported high-risk p53 response element variant on the KITLG promotor was unable to predict (pre)malignancy. Looking in more detail at the individuals SNPs, homozygosity for the risk allele was present in all pre-GCNIS cases for SNPs in two relevant genes, namely in KITLG (rs995030) and in ATF7IP (rs2900333), and their allele frequency distribution differed significantly between individuals with and without pre-GCNIS. KITLG is important for GC survival and is aberrantly expressed in TGCT (Stoop et al., 2008) . Activating transcription factor 7-interacting protein (ATF7IP) increases telomerase activity via telomerase reverse transcriptase (TERT), and is overexpressed in various cancers (Turnbull et al., 2010) . These findings suggest that homozygosity for these risk alleles may play a crucial role in the development of (the precursor of) TGCT in AIS. However, these data need further confirmation.
Of note, the risk alleles examined here have been related to invasive TGCT. We cannot exclude that only some of these, possibly in combination with other, hitherto unknown SNPs, are more relevant for the development of GCNIS. Moreover, currently known TGCT SNPs account for only a small portion of the genetic heritability (Litchfield et al., 2015) . In five of seven pre-GCNIS cases, the AR mutation was in the ligand-binding domain. It is currently not known if the AR genotype or other factors, such as the number of CAG repeats, which has been shown to modulate androgen sensitivity and to correlate with testicular cancer risk in typical men, may influence TGCT susceptibility in AIS (Grassetti et al., 2015) .
Individuals who had pre-GCNIS were relatively young, indicating that these changes are present at an early age. Thus, a screening biopsy to exclude pre-GCNIS, if deemed necessary, may be informative after completion of puberty, with the limitation that such a biopsy is not necessarily representative of the testis as a whole. It is worth noting that no neoplasia was present in samples from much older individuals, even up to 54 years of age, suggesting that individual factors other than age likely play important roles. In spite of a relatively high frequency of pre-GCNIS (10% in PAIS, 14% in CAIS in our study), reassuringly, no invasive TGCT or extensive GCNIS was found in our series or in other published reports. Indeed, regardless of the many women who decline gonadectomy and an estimated large number of individuals with AIS who do not obtain medical care, especially in resource-limited countries, reports of invasive TGCT in AIS adults are extremely rare (Cheikhelard et al., 2008; Audi et al., 2010; Juniarto et al., 2013; Nakhal et al., 2013) . This finding suggests that only a small minority of these pre-GCNIS lesions will become invasive, a hypothesis in line with a previous study of our group (Kaprova-Pleskacova et al., 2014), possibly related to insufficient androgen signaling to promote GC proliferation as outlined above. It remains to be identified what the determining factors are in this particular process, in which particular risk alleles might be involved. Overall, our findings support the rationale of an individualized management approach, based on informed decision making, rather than prophylactic removal of testes in all adults with CAIS. Apart from percentage risk for pre-GCNIS, GCNIS or malignant TGCT, factors such as limited availability of data in older individuals with retained gonads, absence of reliable tumor markers and imaging technologies, or eventual health consequences resulting from unphysiological hormone replacement therapy after gonadectomy, should be discussed.
In conclusion, we have shown that the prevalence of the earliest neoplastic lesion, pre-GCNIS, in individuals with CAIS and PAIS, ranging in age from 14 to 54 years is 10-15%; current data suggest, however, that only a very small minority of these lesions will ever progress to invasive TGCT, questioning the current practice of prophylactic gonadectomy in AIS, even in adults. Individuals with pre-GCNIS had a significantly greater genetic susceptibility to development of TGCT based on presence of risk alleles for genes associated with TGCT. Although, a specific set of SNPs has been found to predict development of invasive TGCT in the testes of typical men, a SNPbased screening test for AIS, such as that applied here, is in its current form, insufficiently discriminatory to be used as a clinical management tool.
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